The frequency and VEN-analysis of pharmacotherapy in children with ARVI in the healthcare institution of the Poltava region
Keywords:acute respiratory viral infections, clinical and economic analysis, VEN analysis, frequency analysis
Acute respiratory viral infections (ARVI) are diseases that have important medico-social importance since they are associated with a wide distribution among the population, the risk of complications, reduced quality of life of patients, and high total cost of treatment.
Aim. To assess the quality of pharmacotherapy: the frequency of prescribing drugs for children with ARVI in the healthcare institution of the Poltava region and the correspondence of drug prescriptions to clinical protocols for providing medical care and the State Formulary of Medicines of Ukraine (SFMU).
Materials and methods. The quality assessment of pharmacotherapy of children with ARVI was performed using auxiliary clinical and economic methods – the frequency and formal VEN-analyses.
Results. The main directions of pharmacotherapy of children with ARVI in one of the healthcare institution of the Poltava region correspond to the unified clinical protocol of the primary care for adults and children with ARVI and clinical protocols for pharmacotherapy of concomitant diseases. Using the formal VEN-analysis it has been determined that the majority of INN drugs prescribed are recommended by clinical protocols for pharmacotherapy of the main (ARVI) and associated diseases registered in patients, and are available in the SFMU (87.50 and 54.69 %, respectively).Conclusions. The formal VEN analysis has shown that the ARVI pharmacotherapy correction is needed in the healthcare institution of the Poltava region studied since a significant part of the INN drugs prescribed is absent in the SFMU (45.31 %) and in clinical protocols for the primary pharmacotherapy (ARVI) and associated diseases (17.19 %). In both medical and technological documents there are no 12.50 % of INNs prescribed. For them 11.74 % of funds (4808.81 UAH) were spent by parents of sick children; they were prescribed 8.74 % times (38 prescriptions) of the total number of prescriptions – 431.
Smiian, O. I., Bynda, T. P., Dmitrova, Ye. V., Sukharieva, V. A. (2013). Zhurnal klinichnykh ta eksperymentalnykh medychnykh doslidzhen, 1 (3), 328–336.
Bogomolov, B. P. (2007). Infekcionnye bolezni: neotlozhnaja diagnostika, lechenie, profilaktika. Moscow: N’judiamed, 653.
Zupanets, I. A., Georgijanc, M. A., Bezuglaja, N. P. (2014). Liki Ukraini, 5-6 (181–182), 5–9.
Nakaz MOZU vid 16.07.2014 № 499. (2014). Unifikovanyi klinichnyi protokol pervynnoi medychnoi dopomohy doroslym ta ditiam. Hostri respiratorni infektsii. Available at: http://moz.gov.ua/ua/portal/dn_20140716_0499.htm
Boriskin, Y., Leneva, I., Pecheur, E., Polyak, S. (2008). Arbidol: a broad–spectrum antiviral compound that bloks viral fusion. Current Med. Chem., 15, 997–1005.
Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V., Mishchenko, O. Ya., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., ... Dumenko, T. M. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno-profilaktychnomu zakladi (suprovid formuliarnoi systemy) : metodychni rekomendatsii. Kharkiv: Styl-Yzdat, 36.
7. Derzhavnyi formuliar likarskykh zasobiv. (2016). Kyiv: DP «Derzhavnyi ekspertnyi tsentr MOZ Ukrainy», 1076.
8. Nakaz MOZ Ukrainy № 566 vid 23.11.2004 r. (2004). Klinichnyi protokol «Kandydozy slyzovoi obolonky porozhnyny rota: hostryi perebih». Available at: http://medstandart.net/browse/1469
Nakaz MOZ Ukrainy № 868 vid 08 zhovtnia 2013 r. (2013). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) medychnoi dopomohy «Bronkhialna astma u ditei». Available at: http://mtd.dec.gov.ua/images/dodatki/2013_868BA_dor_dit/2013_868_ykpmd_BA_dity.pdf
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).